US2005158358A1PendingUtilityA1

Tissue engineering scaffolds promoting matrix protein production

56
Assignee: UNIV RICE WILLIAM MPriority: Aug 21, 2000Filed: Dec 21, 2004Published: Jul 21, 2005
Est. expiryAug 21, 2020(expired)· nominal 20-yr term from priority
Inventors:Jennifer L. WestBrenda K. Mann
A61P 19/00A61P 17/02A61L 2300/414A61L 27/54Y10S530/816A61L 27/52
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides tissue engineering scaffolds capable of inducing extracellular matrix production by a cell attached to the tissue engineering scaffolds, the tissue engineering scaffolds comprising: a scaffold; a polymer tether covalently coupled to the scaffold; and a TGF-β molecule that is covalently coupled to the polymer tether, wherein the TGF-β molecule is present at a concentration sufficient to elicit production of extracellular matrix by the cell attached to the tissue engineering scaffold without increasing cellular proliferation of the attached cell.

Claims

exact text as granted — not AI-modified
1 . A tissue engineering scaffold capable of inducing extracellular matrix production by a cell attached to the tissue engineering scaffold without increasing cellular proliferation of the attached cell, the tissue engineering scaffold comprising: 
 a scaffold;    a polymer tether covalently coupled to the scaffold; and    a TGF-β molecule that is covalently coupled to the polymer tether, wherein the TGF-β molecule is present at a concentration sufficient to elicit production of extracellular matrix by the cell attached to the tissue engineering scaffold without increasing cellular proliferation of the attached cell.    
     
     
         2 . The tissue engineering scaffold of  claim 1  further comprising a cell attached to the tissue engineering scaffold.  
     
     
         3 . The tissue engineering scaffold of  claim 2  wherein the cell is attached to the tissue engineering scaffold by constraining the cell within the scaffold.  
     
     
         4 . The tissue engineering scaffold of  claim 3  wherein the scaffold is a hydrogel.  
     
     
         5 . The tissue engineering scaffold of  claim 2  wherein the cell is selected from the group consisting of smooth muscle cells, endothelial cells, fibroblasts, chondrocytes, and combinations thereof.  
     
     
         6 . The tissue engineering scaffold of  claim 1  wherein the polymer tether has a molecular weight of between about 200 and about 10,000.  
     
     
         7 . The tissue engineering scaffold of  claim 1  wherein the tether has a molecular weight of between about 2,000 and about 6,000.  
     
     
         8 . The tissue engineering scaffold of  claim 1  wherein the scaffold is formed from a biocompatible polymer selected from the group consisting of a synthetic polymer, a natural polymer, an inorganic material, and a combination thereof.  
     
     
         9 . The tissue engineering scaffold of  claim 1  wherein the scaffold is formed from a biocompatible natural polymer, and wherein the biocompatible natural polymer is selected from the group consisting of a collagen, a hyaluronic acid, an albumin, and a combination thereof.  
     
     
         10 . The tissue engineering scaffold of  claim 1  wherein the scaffold is formed from a biocompatible inorganic material, and wherein the biocompatible inorganic material is selected from the group consisting of a hydroxyapatite, a silicone, and a combination thereof.  
     
     
         11 . The tissue engineering scaffold of  claim 1  wherein the scaffold is formed from a biocompatible synthetic polymer, and wherein the biocompatible synthetic polymer is selected from the group consisting of an ethylene vinyl acetate, a poly(meth)acrylate, and a combination thereof.  
     
     
         12 . The tissue engineering scaffold of  claim 1  wherein the scaffold is formed from a biocompatible biodegradable polymer.  
     
     
         13 . The tissue engineering scaffold of  claim 1  wherein the scaffold is formed from a biocompatible biodegradable polymer, and wherein the biocompatible biodegradable polymer is selected from the group consisting of a polyhydroxyacid, a polylactic acid, a polyglycolic acid, a polyanhydride, a polyorthoester, and a combination thereof.  
     
     
         14 . The tissue engineering scaffold of  claim 1  wherein the scaffold is formed from a biocompatible polymer that is not biodegradable.  
     
     
         15 . The tissue engineering scaffold of  claim 1  wherein the scaffold is formed from a biocompatible polymer that is a hydrogel.  
     
     
         16 . The tissue engineering scaffold of  claim 1  wherein the scaffold is formed from a biocompatible polymer that is a polyethylene glycol-diacrylate polymer hydrogel.  
     
     
         17 . The tissue engineering scaffold of  claim 1  wherein the scaffold is formed from a biocompatible polymer that is an alginate hydrogel.  
     
     
         18 . The tissue engineering scaffold of  claim 1  wherein the scaffold is formed from a biocompatible polymer that is a malleable, ionic hydrogel.  
     
     
         19 . A tissue engineering scaffold capable of inducing extracellular matrix production by a cell attached to the tissue engineering scaffold without increasing cellular proliferation of the attached cell, the tissue engineering scaffold comprising: 
 a scaffold;    a polymer tether covalently coupled to the scaffold; and    a TGF-β molecule that is covalently coupled to the polymer tether, wherein the TGF-β molecule is present at a concentration in the range of from about 4×10 −6  to about 4×10 −3  nmol/mL.    
     
     
         20 . The tissue engineering scaffold of  claim 19 , further comprising a cell attached to the tissue engineering scaffold.  
     
     
         21 . A tissue engineering scaffold capable of inducing extracellular matrix production by a cell attached to the tissue engineering scaffold without increasing cellular proliferation of the attached cell, the tissue engineering scaffold comprising: 
 a scaffold, at least a portion of the scaffold comprising a hydrogel;    a polymer tether covalently coupled to the scaffold; and    a TGF-β molecule that is covalently coupled to the polymer tether, wherein the TGF-β molecule is present at a concentration in the range of from about 4×10 −6  to about 4×10 −3  nmol/mL.    
     
     
         22 . The tissue engineering scaffold of  claim 21 , further comprising a cell attached to the tissue engineering scaffold.

Join the waitlist — get patent alerts

Track US2005158358A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.